ClinicalTrials.gg
TerminatedNCT04859517EVADEUpdated Aug 20, 2024Results posted

Evaluation of ADG20 for the Prevention of COVID-19

A Phase 2/3 interventional study of ADG20 and Placebo in COVID-19, sponsored by Invivyd, Inc.. Terminated at 95 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Invivyd, Inc. · Phase 2/3, Interventional, and Prevention

How we know

Why this study was terminated
All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
2,582
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
97th of 1,322
2,582 · median 92
Started
2021
with 503 others
Phase 2/3
70 of 1,860
1 open now
Registered
1,099th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 97th largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 70 in phase 2/3, and was the 1,099th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.

Read the detailed description

Phase 2/3, multicenter, double-blind, placebo-controlled, randomized study of the mAb ADG20 in the prevention of symptomatic COVID-19 in adults and adolescents with no known history of SARS-CoV-2 infection but whose circumstances place them at increased risk of acquiring SARS-CoV-2 infection and developing symptomatic COVID-19. This objective was independently evaluated in a cohort of participants with reported recent exposure to an individual diagnosed with a SARS-CoV-2 infection (post-exposure prophylaxis) and in a cohort of participants with no reported exposure to SARS-CoV-2 (pre-exposure prophylaxis). These cohorts included participants whose advanced age (≥55 years old) or health status placed them at risk for severe COVID-19 or COVID-19 complications.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Adintrevimab, ADG20, COVID-19, prevention, prophylaxis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Tests negative for current or previous SARS-CoV-2 infection by RT-PCR and serology (Pre-exposure population only)
  • Is at high risk of SARS-CoV-2 infection as assessed by the Investigator:

    1. Post-exposure population: exposure to an individual with a diagnosis of SARS-CoV-2 infection (index case). Note: Participants with recent exposure to a laboratory-confirmed index case must be asymptomatic and randomized within 5 days (120 hours) of collection of the index case's positive SARS-CoV-2 diagnostic test.
    2. Pre-exposure population: Occupational, housing, recreational and/or social conditions that are likely to increase risk of exposure to SARS-CoV-2.
  • Agrees to defer receipt of COVID-19 vaccination for minimum of 180 days (6 months) after dosing

Exclusion criteria

Exclusion Criteria:

  • Has received (1) a SARS-CoV-2 vaccine, (2) mAb or (3) convalescent plasma from a person who has recovered from COVID-19 or prior participation in SARS-CoV2 vaccine, convalescent plasma, or mAb clinical trial any time prior to participation in the study.
  • Receipt of any product within 30 days or 5 half lives before the day of enrollment.
  • Is acutely ill or febrile 72 hours before or at Screening or has other COVID-19 symptoms including cough, fatigue, muscle or body aches, headache, or loss of taste or smell. Fever is defined as a body temperature ≥38.0°C (≥100.4°F).
  • Has received or plans to receive a non-COVID-19 vaccine within 28 days before or after dosing (except for seasonal influenza vaccine, which is not permitted within 14 days before or after dosing).

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,582 participants (actual)

Study arms

  • Experimental
    ADG20

    Participants will be dosed on Day 1 with ADG20 IM

    Drug: ADG20

  • Placebo comparator
    Placebo

    Participants will be dosed on Day 1 with placebo IM

    Drug: Placebo

Interventions

  • DrugADG20

    Single dose of ADG20

  • DrugPlacebo

    Single dose of placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)

    RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.

    Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  2. Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP)

    RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.

    Time frame: Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier

  3. Solicited Injection Site Reactions (PEP, PrEP)

    Percentage of participants with at least one solicited injection site reaction

    Time frame: Day 1 through Day 4

  4. Participants With at Least 1 Treatment Emergent Adverse Events (PEP, PrEP)

    Any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment; includes solicited injection site reactions

    Time frame: Day 1 through 14 Months or 25Jul2022, whichever is earlier

Secondary outcomes

  1. Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)

    RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCRtest from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.

    Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  2. Percentage of Participants With SARS-CoV-2 Infection (Asymptomatic or Symptomatic) as Determined by Positive RT-PCR or Serology (PEP)

    Participants with RT-PCR-confirmed symptomatic COVID-19 (protocol defined COVID-19 symptoms occurring within 14 days from the sample collection date of a positive central or local \[in the absence of central test\] RT-PCR, any COVID-19-related hospitalization with a positive local SARS-CoV-2 test \[within 14 days\], or all-cause death), central RT-PCR-confirmed SARS-CoV-2 infection, or central serology-confirmed SARS-CoV-2 infection with negative central serology at baseline.

    Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  3. Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by RT-PCR (PEP)

    Defined as having a central RT-qPCR-confirmed SARS-CoV-2 infection without having an RT-PCR-confirmed symptomatic COVID-19 outcome

    Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  4. Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PEP)

    Defined as having a central serology-confirmed SARS-CoV-2 infection (with a negative central serology test sample at baseline) and without having an RT-PCR-confirmed symptomatic COVID-19 outcome (including COVID-19-related hospitalization and all-cause death)

    Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  5. Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PrEP)

    Defined as having a central serology-confirmed SARS-CoV-2 infection (with a negative central serology test sample at baseline) and without having an RT-PCR-confirmed symptomatic COVID-19 outcome (including COVID-19-related hospitalization and all-cause death)

    Time frame: Day 1 through 6 Months or emergence of Omicron (15-Dec-2021), whichever is earlier

  6. SARS-CoV-2 Viral Load as Assessed by RT-qPCR Change From Baseline in Asymptomatic Participants (PEP)

    Asymptomatic SARS-CoV-2 infection confirmed by RT-qPCR from nasal swab collected at Day 8 and Day 15. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).

    Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  7. Percentage of Participants With RT-PCR Confirmed Mild, Moderate, or Severe/Critical COVID-19 (PEP)

    Maximum severity assessed from COVID-19-like illness (CLI) Day 1 through CLI Day 28. COVID-19-related hospitalizations or COVID-19-related deaths from CLI Day 1 to CLI Day 28 are categorized as severe/critical.

    Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  8. Percentage of Participants With RT-PCR Confirmed Mild, Moderate, or Severe/Critical COVID-19 (PrEP)

    Maximum severity assessed from COVID-19-like Illness (CLI) Day 1 through CLI Day 28. COVID-19-related hospitalizations or COVID-19-related deaths from CLI Day 1 to CLI Day 28 are categorized as severe/critical.

    Time frame: Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier

  9. Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP)

    Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR-confirmed symptomatic COVID-19 events, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.

    Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  10. Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP)

    Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR confirmed symptomatic COVID-19, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.

    Time frame: Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier

  11. Percentage of Participants With a COVID-19 Related Hospitalization (PEP)

    Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)

  12. Percentage of Participants With a COVID-19 Related Hospitalization (PrEP)

    Time frame: Through 28 days from COVID-19-like illness initial visit (CLI Day 1)

  13. COVID-19 Related Mortality (PEP)

    Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)

  14. COVID-19 Related Mortality (PrEP)

    Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)

  15. All-Cause Mortality (PEP)

    Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)

  16. All-Cause Mortality (PrEP)

    Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)

  17. Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PEP)

    Viral load from COVID-19-like illness (CLI) Day 1 sample. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).

    Time frame: Positive CLI Day 1 sample through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier

  18. Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PrEP)

    Viral load from COVID-19-like Illness (CLI) Day 1 sample. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).

    Time frame: Positive CLI Day 1 sample through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier

  19. Assessment of PK Parameter: ADG20 Plasma Concentrations (PEP)

    PK samples collected at protocol-defined timepoints

    Time frame: Day 1 through 12 Months or end of study (11-Jan-2022), whichever is earlier

  20. Assessment of PK Parameter: ADG20 Plasma Concentrations (PrEP)

    PK samples collected at protocol-defined timepoints

    Time frame: Day 1 through 12 Months or end of study (11-Jan-2022), whichever is earlier

  21. Time From Randomization to First RT-PCR-confirmed Symptomatic COVID-19 (PEP)

    Outcome measure is presented as cumulative probability expressed in percentage. RT-PCR-confirmed symptomatic COVID-19 event is defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.

    Time frame: An average of 2 months up to 7 months through cutoff date prior to emergence of Omicron (15-Dec-2021)

  22. Time From Randomization to First RT-PCR-confirmed Symptomatic COVID-19 (PrEP)

    Outcome measure is presented as cumulative probability expressed in percentage. RT-PCR-confirmed symptomatic COVID-19 event is defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.

    Time frame: An average of 2.5 months up to 7.5 months through cutoff date prior to emergence of Omicron (15-Dec-2021)

07

Results

Posted Aug 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort B
Started24524210481047
Completed3235226236
Not completed213207822811

Outcome measures

PrimaryPercentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)

RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.

Time frame:
Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)312
Statistical analysis
  • ADG20 IM - Cohort A vs Placebo IM - Cohort A · Regression, Logistic · p = 0.0123 · Risk difference (rd): -5.0 · 95% CI -8.87 to -1.08
PrimaryPercentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP)

RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.

Time frame:
Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP)
ParticipantsADG20 IM - Cohort BPlacebo IM - Cohort B
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP)1240
Statistical analysis
  • ADG20 IM - Cohort B vs Placebo IM - Cohort B · Regression, Logistic · p = <0.0001 · Risk difference (rd): -3.9 · 95% CI -5.75 to -2.01
PrimarySolicited Injection Site Reactions (PEP, PrEP)

Percentage of participants with at least one solicited injection site reaction

Time frame:
Day 1 through Day 4
Reported as:
Count of participants · Participants
Solicited Injection Site Reactions (PEP, PrEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort B
Solicited Injection Site Reactions (PEP, PrEP)1277573
PrimaryParticipants With at Least 1 Treatment Emergent Adverse Events (PEP, PrEP)

Any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment; includes solicited injection site reactions

Time frame:
Day 1 through 14 Months or 25Jul2022, whichever is earlier
Reported as:
Count of participants · Participants
Participants With at Least 1 Treatment Emergent Adverse Events (PEP, PrEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort B
Participants With at Least 1 Treatment Emergent Adverse Events (PEP, PrEP)4251399362
SecondaryPercentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)

RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCRtest from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.

Time frame:
Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)17
Statistical analysis
  • ADG20 IM - Cohort A vs Placebo IM - Cohort A · Regression, Logistic · p = 0.0153 · Standardized risk difference: -7.6 · 95% CI -13.74 to -1.46
SecondaryPercentage of Participants With SARS-CoV-2 Infection (Asymptomatic or Symptomatic) as Determined by Positive RT-PCR or Serology (PEP)

Participants with RT-PCR-confirmed symptomatic COVID-19 (protocol defined COVID-19 symptoms occurring within 14 days from the sample collection date of a positive central or local \[in the absence of central test\] RT-PCR, any COVID-19-related hospitalization with a positive local SARS-CoV-2 test \[within 14 days\], or all-cause death), central RT-PCR-confirmed SARS-CoV-2 infection, or central serology-confirmed SARS-CoV-2 infection with negative central serology at baseline.

Time frame:
Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With SARS-CoV-2 Infection (Asymptomatic or Symptomatic) as Determined by Positive RT-PCR or Serology (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
Percentage of Participants With SARS-CoV-2 Infection (Asymptomatic or Symptomatic) as Determined by Positive RT-PCR or Serology (PEP)614
Statistical analysis
  • ADG20 IM - Cohort A vs Placebo IM - Cohort A · Regression, Logistic · p = 0.0612 · Risk difference (rd): -4.4 · 95% CI -9.03 to 0.21
SecondaryPercentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by RT-PCR (PEP)

Defined as having a central RT-qPCR-confirmed SARS-CoV-2 infection without having an RT-PCR-confirmed symptomatic COVID-19 outcome

Time frame:
Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by RT-PCR (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by RT-PCR (PEP)31
SecondaryPercentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PEP)

Defined as having a central serology-confirmed SARS-CoV-2 infection (with a negative central serology test sample at baseline) and without having an RT-PCR-confirmed symptomatic COVID-19 outcome (including COVID-19-related hospitalization and all-cause death)

Time frame:
Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PEP)01
SecondaryPercentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PrEP)

Defined as having a central serology-confirmed SARS-CoV-2 infection (with a negative central serology test sample at baseline) and without having an RT-PCR-confirmed symptomatic COVID-19 outcome (including COVID-19-related hospitalization and all-cause death)

Time frame:
Day 1 through 6 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PrEP)
ParticipantsADG20 IM - Cohort BPlacebo IM - Cohort B
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PrEP)1018
SecondarySARS-CoV-2 Viral Load as Assessed by RT-qPCR Change From Baseline in Asymptomatic Participants (PEP)

Asymptomatic SARS-CoV-2 infection confirmed by RT-qPCR from nasal swab collected at Day 8 and Day 15. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).

Time frame:
Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Mean · Viral load (log10 copies/mL)
SARS-CoV-2 Viral Load as Assessed by RT-qPCR Change From Baseline in Asymptomatic Participants (PEP)
Viral load (log10 copies/mL)ADG20 IM - Cohort APlacebo IM - Cohort A
Day 82.96 ± 4.1860 ± 0
Day 152.15 ± 1.9853.16
SecondaryPercentage of Participants With RT-PCR Confirmed Mild, Moderate, or Severe/Critical COVID-19 (PEP)

Maximum severity assessed from COVID-19-like illness (CLI) Day 1 through CLI Day 28. COVID-19-related hospitalizations or COVID-19-related deaths from CLI Day 1 to CLI Day 28 are categorized as severe/critical.

Time frame:
Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With RT-PCR Confirmed Mild, Moderate, or Severe/Critical COVID-19 (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
Cohort A (PEP) Mild37
Cohort A (PEP) Moderate02
Cohort A (PEP) Severe/Critical03
SecondaryPercentage of Participants With RT-PCR Confirmed Mild, Moderate, or Severe/Critical COVID-19 (PrEP)

Maximum severity assessed from COVID-19-like Illness (CLI) Day 1 through CLI Day 28. COVID-19-related hospitalizations or COVID-19-related deaths from CLI Day 1 to CLI Day 28 are categorized as severe/critical.

Time frame:
Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With RT-PCR Confirmed Mild, Moderate, or Severe/Critical COVID-19 (PrEP)
ParticipantsADG20 IM - Cohort BPlacebo IM - Cohort B
Cohort B (PrEP) Mild714
Cohort B (PrEP) Moderate419
Cohort B (PrEP) Severe/Critical17
SecondaryPercentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP)

Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR-confirmed symptomatic COVID-19 events, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.

Time frame:
Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP)03
SecondaryPercentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP)

Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR confirmed symptomatic COVID-19, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.

Time frame:
Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Count of participants · Participants
Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP)
ParticipantsADG20 IM - Cohort BPlacebo IM - Cohort B
Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP)16
SecondaryPercentage of Participants With a COVID-19 Related Hospitalization (PEP)
Time frame:
Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
Reported as:
Count of participants · Participants
Percentage of Participants With a COVID-19 Related Hospitalization (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
Percentage of Participants With a COVID-19 Related Hospitalization (PEP)03
SecondaryPercentage of Participants With a COVID-19 Related Hospitalization (PrEP)
Time frame:
Through 28 days from COVID-19-like illness initial visit (CLI Day 1)
Reported as:
Count of participants · Participants
Percentage of Participants With a COVID-19 Related Hospitalization (PrEP)
ParticipantsADG20 IM - Cohort BPlacebo IM - Cohort B
Percentage of Participants With a COVID-19 Related Hospitalization (PrEP)16
SecondaryCOVID-19 Related Mortality (PEP)
Time frame:
Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
Reported as:
Count of participants · Participants
COVID-19 Related Mortality (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
COVID-19 Related Mortality (PEP)00
SecondaryCOVID-19 Related Mortality (PrEP)
Time frame:
Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
Reported as:
Count of participants · Participants
COVID-19 Related Mortality (PrEP)
ParticipantsADG20 IM - Cohort BPlacebo IM - Cohort B
COVID-19 Related Mortality (PrEP)01
SecondaryAll-Cause Mortality (PEP)
Time frame:
Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
Reported as:
Count of participants · Participants
All-Cause Mortality (PEP)
ParticipantsADG20 IM - Cohort APlacebo IM - Cohort A
All-Cause Mortality (PEP)00
SecondaryAll-Cause Mortality (PrEP)
Time frame:
Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
Reported as:
Count of participants · Participants
All-Cause Mortality (PrEP)
ParticipantsADG20 IM - Cohort BPlacebo IM - Cohort B
All-Cause Mortality (PrEP)01
SecondaryViral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PEP)

Viral load from COVID-19-like illness (CLI) Day 1 sample. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).

Time frame:
Positive CLI Day 1 sample through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Mean · log10 copies/mL
Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PEP)
log10 copies/mLADG20 IM - Cohort APlacebo IM - Cohort A
Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PEP)2.43 ± 2.3725.74 ± 2.689
SecondaryViral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PrEP)

Viral load from COVID-19-like Illness (CLI) Day 1 sample. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).

Time frame:
Positive CLI Day 1 sample through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Reported as:
Mean · Log10 copies/mL
Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PrEP)
Log10 copies/mLADG20 IM - Cohort BPlacebo IM - Cohort B
Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PrEP)4.58 ± 2.7306.58 ± 1.825
SecondaryAssessment of PK Parameter: ADG20 Plasma Concentrations (PEP)

PK samples collected at protocol-defined timepoints

Time frame:
Day 1 through 12 Months or end of study (11-Jan-2022), whichever is earlier
Reported as:
Mean · ug/mL
Assessment of PK Parameter: ADG20 Plasma Concentrations (PEP)
ug/mLADG20 IM - Cohort A
Day 836.3 ± 15.4
Day 2833.6 ± 12.6
SecondaryAssessment of PK Parameter: ADG20 Plasma Concentrations (PrEP)

PK samples collected at protocol-defined timepoints

Time frame:
Day 1 through 12 Months or end of study (11-Jan-2022), whichever is earlier
Reported as:
Mean · ug/mL
Assessment of PK Parameter: ADG20 Plasma Concentrations (PrEP)
ug/mLADG20 IM - Cohort B
Day 838.2 ± 14.7
Day 2833.6 ± 12.5
SecondaryTime From Randomization to First RT-PCR-confirmed Symptomatic COVID-19 (PEP)

Outcome measure is presented as cumulative probability expressed in percentage. RT-PCR-confirmed symptomatic COVID-19 event is defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.

Time frame:
An average of 2 months up to 7 months through cutoff date prior to emergence of Omicron (15-Dec-2021)
Reported as:
Number · Percent probability
Time From Randomization to First RT-PCR-confirmed Symptomatic COVID-19 (PEP)
Percent probabilityADG20 IM - Cohort APlacebo IM - Cohort A
Day 281.747.01
Day 601.747.84
Day 901.747.84
Statistical analysis
  • ADG20 IM - Cohort A vs Placebo IM - Cohort A · Log Rank · p = 0.0077 · Hazard ratio (hr): 0.22 · 95% CI 0.06 to 0.76
SecondaryTime From Randomization to First RT-PCR-confirmed Symptomatic COVID-19 (PrEP)

Outcome measure is presented as cumulative probability expressed in percentage. RT-PCR-confirmed symptomatic COVID-19 event is defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.

Time frame:
An average of 2.5 months up to 7.5 months through cutoff date prior to emergence of Omicron (15-Dec-2021)
Reported as:
Number · Percent probability
Time From Randomization to First RT-PCR-confirmed Symptomatic COVID-19 (PrEP)
Percent probabilityADG20 IM - Cohort BPlacebo IM - Cohort B
Day 280.962.32
Day 601.315.64
Day 902.017.26
Statistical analysis
  • ADG20 IM - Cohort B vs Placebo IM - Cohort B · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.27 · 95% CI 0.14 to 0.49

Adverse events

Collected over Baseline through Month 14 or end of study (11-Jan-2022), whichever is earlier. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADG20 IM - Cohort A0/240 (0%)4/240 (1.7%)0/240 (0%)
Placebo IM - Cohort A2/241 (0.8%)8/241 (3.3%)0/241 (0%)
ADG20 IM - Cohort B3/1,001 (0.3%)46/1,001 (4.6%)126/1,001 (12.6%)
Placebo IM - Cohort B6/1,001 (0.6%)46/1,001 (4.6%)123/1,001 (12.3%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort B
COVID-19 pneumoniaInfections and infestations1/2404/2411/10019/1001
COVID-19Infections and infestations0/2400/2413/10016/1001
PneumoniaInfections and infestations1/2400/2414/10012/1001
Abortion spontaneous incompletePregnancy, puerperium and perinatal conditions1/2400/2410/10010/1001
GoutMetabolism and nutrition disorders1/2400/2410/10010/1001
InfluenzaInfections and infestations0/2401/2410/10010/1001
Toxicity to various agentsInjury, poisoning and procedural complications0/2401/2410/10011/1001
Gun shot woundInjury, poisoning and procedural complications0/2401/2411/10011/1001
ContusionInjury, poisoning and procedural complications0/2401/2410/10010/1001
Hip fractureInjury, poisoning and procedural complications0/2400/2410/10012/1001
Most frequent other events
Most frequent other events
EventADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort B
Injection site painGeneral disorders——76/100184/1001
Influenza like illnessGeneral disorders——59/100146/1001

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort BTotal
<=18 years527216
Between 18 and 65 years2092209429232294
>=65 years312099122272
Age, Continuous
Age, Continuous(years)ADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort BTotal
Mean45.4 ± 15.6145.4 ± 14.5246.5 ± 13.9047.1 ± 14.1046.8 ± 14.00
Sex: Female, Male
Sex: Female, Male(Participants)ADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort BTotal
Female1231205085221273
Male1221225405251309
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort BTotal
Hispanic or Latino146143217248754
Not Hispanic or Latino99997857511734
Unknown or Not Reported00464894
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort BTotal
American Indian or Alaska Native0051217
Asian0010818
Native Hawaiian or Other Pacific Islander106613
Black or African American2930168182409
White2142108218032048
More than one race01151127
Unknown or Not Reported11232550
Region of Enrollment
Region of Enrollment(participants)ADG20 IM - Cohort APlacebo IM - Cohort AADG20 IM - Cohort BPlacebo IM - Cohort BTotal
Argentina016714
Romania43360079
United States1801808708682098
Czechia00358
Ukraine22258281210
Poland00171633
Moldova00527
Georgia006568133
08

Study locations

95 sites
  • Invivyd Investigative Site
    Birmingham, Alabama 35209, United States
  • Invivyd Investigative Site
    Tucson, Arizona 85745, United States
  • Invivyd Investigative Site
    Fayetteville, Arkansas 72701, United States
  • Invivyd Investigative Site
    North Little Rock, Arkansas 72223, United States
  • Invivyd Investigative Site
    Banning, California 92220, United States
  • Invivyd Investigative Site
    Chula Vista, California 91911, United States
  • Invivyd Investigative Site
    Culver City, California 90230, United States
  • Invivyd Investigative Site
    Escondido, California 92025, United States
  • Invivyd Investigative Site
    Fullerton, California 92835, United States
  • Invivyd Investigative Site
    Long Beach, California 90806, United States
  • Invivyd Investigative Site
    Los Angeles, California 90036, United States
  • Invivyd Investigative Site
    Modesto, California 95350, United States
  • Invivyd Investigative Site
    Palm Springs, California 92262, United States
  • Invivyd Investigative Site
    San Diego, California 92103, United States
  • Invivyd Investigative Site
    Clearwater, Florida 33756, United States
  • Invivyd Investigative Site
    Edgewater, Florida 32132, United States
  • Invivyd Investigative Site
    Hialeah, Florida 33012, United States
  • Invivyd Investigative Site
    Miami, Florida 33155, United States
  • Invivyd Investigative Site
    Miami, Florida 33176, United States
  • Invivyd Investigative Site
    Miami, Florida 33186, United States
  • Invivyd Investigative Site
    Mount Dora, Florida 32757, United States
  • Invivyd Investigative Site
    North Miami Beach, Florida 33169, United States
  • Invivyd Investigative Site
    Ormond Beach, Florida 32174, United States
  • Invivyd Investigative Site
    Pembroke Pines, Florida 33026, United States
  • Invivyd Investigative Site
    Sunrise, Florida 33325, United States
  • Invivyd Investigative Site
    Tampa, Florida 33603, United States
  • Invivyd Investigative Site
    The Villages, Florida 32159, United States
  • Invivyd Investigative Site
    West Palm Beach, Florida 33409, United States
  • Invivyd Investigative Site
    Hinesville, Georgia 31313, United States
  • Invivyd Investigative Site
    Lawrenceville, Georgia 30044, United States
  • Invivyd Investigative Site
    Pearl City, Hawaii 96782, United States
  • Invivyd Investigative Site
    Chicago, Illinois 60607, United States
  • Invivyd Investigative Site
    Oak Brook, Illinois 60523, United States
  • Invivyd Investigative Site
    Owensboro, Kentucky 42303, United States
  • Invivyd Investigative Site
    Marrero, Louisiana 70072, United States
  • Invivyd Investigative Site
    New Orleans, Louisiana 70118, United States
  • Invivyd Investigative Site
    Rockville, Maryland 20855, United States
  • Invivyd Investigative Site
    Burlington, Massachusetts 01803, United States
  • Invivyd Investigative Site
    Caro, Michigan 48723, United States
  • Invivyd Investigative Site
    Grosse Pointe Woods, Michigan 48236, United States
  • Invivyd Investigative Site
    Missoula, Montana 59808, United States
  • Invivyd Investigative Site
    Albuquerque, New Mexico 87102, United States
  • Invivyd Investigative Site
    New York, New York 11201, United States
  • Invivyd Investigative Site
    Charlotte, North Carolina 28208, United States
  • Invivyd Investigative Site
    Shelby, North Carolina 28150, United States
  • Invivyd Investigative Site
    Beachwood, Ohio 44122, United States
  • Invivyd Investigative Site
    Cincinnati, Ohio 54242, United States
  • Invivyd Investigative Site
    Dresden, Ohio 43821, United States
  • Invivyd Investigative Site
    Middleburg Heights, Ohio 44130, United States
  • Invivyd Investigative Site
    Yukon, Oklahoma 73099, United States
  • Invivyd Investigative Site
    Medford, Oregon 97504, United States
  • Invivyd Investigative Site
    West Columbia, South Carolina 29169, United States
  • Invivyd Investigative Site
    Jackson, Tennessee 38305, United States
  • Invivyd Investigative Site
    Milan, Tennessee 38358, United States
  • Invivyd Investigative Site
    Nashville, Tennessee 37203, United States
  • Invivyd Investigative Site
    Beaumont, Texas 77706, United States
  • Invivyd Investigative Site
    College Station, Texas 77845, United States
  • Invivyd Investigative Site
    Corpus Christi, Texas 78412, United States
  • Invivyd Investigative Site
    Houston, Texas 77022, United States
  • Invivyd Investigative Site
    Houston, Texas 77087, United States
  • Invivyd Investigative Site
    Hurst, Texas 76054, United States
  • Invivyd Investigative Site
    Mesquite, Texas 75149, United States
  • Invivyd Investigative Site
    Sugar Land, Texas 77479, United States
  • Invivyd Investigative Site
    Saint George, Utah 84790, United States
  • Invivyd Investigative Site
    West Jordan, Utah 84088, United States
  • Invivyd Investigative Site
    Richmond, Virginia 23226, United States
  • Invivyd Investigative Site
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1426ABP, Argentina
  • Invivyd Investigative Site
    Mar Del Plata, Buenos Aires B7600FZO, Argentina
  • Invivyd Investigative Site
    Munro, Buenos Aires B1605FRE, Argentina
  • Invivyd Investigative Site
    Ramos Mejía, Buenos Aires B1704ETD, Argentina
  • Invivyd Investigative Site
    Rosario, Santa Fe S2000, Argentina
  • Invivyd Investigative Site
    Rosario, Sante Fe S2000, Argentina
  • Invivyd Investigative Site
    Ostrava, 708 00, Czechia
  • Invivyd Investigative Site
    Praha, 158 00, Czechia
  • Invivyd Investigative Site
    Rychnov Nad Kněžnou, 516 01, Czechia
  • Invivyd Investigative Site
    Batumi, 6000, Georgia
  • Invivyd Investigative Site
    Kutaisi, 4600, Georgia
  • Invivyd Investigative Site
    Rust'avi, 3700, Georgia
  • Invivyd Investigative Site
    Tbilisi, 0179, Georgia
  • Invivyd Investigative Site
    Tbilisi, 0180, Georgia
  • Invivyd Investigative Site
    Tbilisi, 0186, Georgia
  • Invivyd Investigative Site
    Tbilisi, 0197, Georgia
  • Invivyd Investigative Site
    Berlin, 10629, Germany
  • Invivyd Investigative Site
    Chisinau, 2025, Moldova, Republic of
  • Invivyd Investigative Site
    Kajetany, 05-830, Poland
  • Invivyd Investigative Site
    Lublin, 20-412, Poland
  • Invivyd Investigative Site
    Siedlce, 08-110, Poland
  • Invivyd Investigative Site
    Skierniewice, 96-100, Poland
  • Invivyd Investigative Site
    Warszawa, 02-793, Poland
  • Invivyd Investigative Site
    Zamość, 22-400, Poland
  • Invivyd Investigative Site
    Łódź, 90-302, Poland
  • Invivyd Investigative Site
    Świdnica, 58-100, Poland
  • Invivyd Investigative Site
    Bucuresti, 021105, Romania
  • Adagio Investigative Site
    Kyiv, 01103, Ukraine
  • Invivyd Investigative Site
    Kyiv, 01135, Ukraine
09

References and documents

Publications

  • Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, Salomon S, Wood EM, So-Osman C, McQuilten Z, Spinner CD, Malin JJ, Stegemann M, Skoetz N, Kreuzberger N. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2. PubMed 35713300 ↗
  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PubMed 34473343 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Nov 2022, 18 months.

Results were first posted in Aug 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 26, 2021
StartActual
Apr 27, 2021
Primary completionActual
Nov 4, 2022
CompletionActual
Nov 4, 2022
Results first posted
Aug 20, 2024
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04859517
Lead sponsor
Invivyd, Inc.
Responsible party
Sponsor
First posted
Apr 26, 2021
Start date
Apr 27, 2021
Primary completion
Nov 4, 2022
Completion
Nov 4, 2022
Results posted
Aug 20, 2024
Last update
Aug 20, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion